AU2022210283A1 - Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody - Google Patents

Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody Download PDF

Info

Publication number
AU2022210283A1
AU2022210283A1 AU2022210283A AU2022210283A AU2022210283A1 AU 2022210283 A1 AU2022210283 A1 AU 2022210283A1 AU 2022210283 A AU2022210283 A AU 2022210283A AU 2022210283 A AU2022210283 A AU 2022210283A AU 2022210283 A1 AU2022210283 A1 AU 2022210283A1
Authority
AU
Australia
Prior art keywords
antibody
patient
tma
syndrome
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022210283A
Other languages
English (en)
Other versions
AU2022210283A9 (en
Inventor
Gin-Fu CHEN
Zeeshan KHAWAJA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2022210283A1 publication Critical patent/AU2022210283A1/en
Publication of AU2022210283A9 publication Critical patent/AU2022210283A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022210283A 2021-01-22 2022-01-18 Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody Pending AU2022210283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163140488P 2021-01-22 2021-01-22
US63/140,488 2021-01-22
PCT/US2022/012739 WO2022159373A1 (en) 2021-01-22 2022-01-18 Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody

Publications (2)

Publication Number Publication Date
AU2022210283A1 true AU2022210283A1 (en) 2023-08-03
AU2022210283A9 AU2022210283A9 (en) 2024-10-17

Family

ID=80820704

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022210283A Pending AU2022210283A1 (en) 2021-01-22 2022-01-18 Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody

Country Status (8)

Country Link
US (1) US20240092881A1 (https=)
EP (2) EP4281472A1 (https=)
JP (1) JP2024504366A (https=)
KR (1) KR20230134533A (https=)
AU (1) AU2022210283A1 (https=)
CA (1) CA3173016A1 (https=)
IL (1) IL304593A (https=)
WO (1) WO2022159373A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873602B1 (en) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
EP4583911A1 (en) * 2022-09-06 2025-07-16 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
TW202426048A (zh) * 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性（ｈｓｃｔ－ｔｍａ）的抗ｃ５抗體的補充劑量和投與

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
WO2014099546A1 (en) 2012-12-19 2014-06-26 Promerus, Llc Process for the preparation of high purity norbornene alkanols and derivatives thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
EP3802603A1 (en) * 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
EP3873602B1 (en) * 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
CN117838856A (zh) * 2019-01-25 2024-04-09 亚力兄制药公司 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
EP3924380A1 (en) * 2019-02-14 2021-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis
WO2021091937A1 (en) * 2019-11-08 2021-05-14 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
CA3173011A1 (en) * 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
IL304593A (en) 2023-09-01
JP2024504366A (ja) 2024-01-31
EP4378479A2 (en) 2024-06-05
AU2022210283A9 (en) 2024-10-17
US20240092881A1 (en) 2024-03-21
CA3173016A1 (en) 2022-07-28
WO2022159373A1 (en) 2022-07-28
EP4281472A1 (en) 2023-11-29
KR20230134533A (ko) 2023-09-21
EP4378479A3 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
JP7577542B2 (ja) 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
JP2025146943A (ja) 発作性夜間ヘモグロビン尿症（ＰＮＨ）および非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量および投与
ES2980453T3 (es) Dosificación y administración de anticuerpos anti-c5 para el tratamiento del síndrome urémico hemolítico atípico (ahus)
US20190023775A1 (en) Dosage and administration of anti-c5 antibodies for treatment
US20240092881A1 (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20200262897A1 (en) Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20180237509A1 (en) Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients
EP4196161A1 (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
HK40110798A (en) Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
US20230172930A1 (en) Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
WO2022060931A1 (en) Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)
JP7734673B2 (ja) 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
RU2822664C2 (ru) ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС)
WO2025166118A1 (en) Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)

Legal Events

Date Code Title Description
SREP Specification republished